First Selective Covalent FGFR3 Inhibitors: Conquering Toxicity and Resistance

Key Points

• The viewpoint discusses the development of selective covalent FGFR3 inhibitors to combat toxicity and resistance in cancer treatments.
• Overview of current pan-FGFR inhibitors and their limitations.
• Introduction of the new FGFR3-selective covalent inhibitor.
• Discussion on the implications of isoform selectivity in cancer therapy.
• The new covalent FGFR3-selective inhibitor shows promise for addressing toxicity issues.
• It may effectively manage clinically acquired resistance in FGFR3-altered cancers.